KORKMAZ, PINARDemirturk, NeseBatirel, AyseTulek, NeclaOzguler, MugeHarman, RezanCinar, GuleTOKA, ONURYoruk, GulsenAtaman-Hatipoglu, CigdemSarigul, FigenSIRMATEL, FATMAImre, AyferMISTANOĞLU ÖZATAĞ, DURUKARAKEÇİLİ, FARUKURAL, ONURSÜMER, ŞUAAktug-Demir, NazlimKadanali, AytenComoglu, SenolUcer, SengulSaltoglu, NeseGunal, OzgurOzkaya, Hacer DenizYenilmez, ErcanCetinkaya, Riza AytacYuksel, EsmaHAKYEMEZ, İSMAİL NECATİMERİÇ KOÇ, MELİHATuncer-Ertem, GunayBestepe-Dursun, ZehraCelik, IlhamiYILMAZ, EMELEvik, GulizKaya, AliSuer, Kaya2020-10-212020-10-212019-12-01KORKMAZ P., Demirturk N., Batirel A., Tulek N., Ozguler M., Harman R., Cinar G., TOKA O., Yoruk G., Ataman-Hatipoglu C., et al., -Effect of Hepatosteatosis on the Virological Response in Entecavir and Tenofovir Therapies-, KLIMIK JOURNAL, cilt.32, ss.265-274, 2019http://hdl.handle.net/20.500.12645/23478Objective: Both chronic hepatitis B (CHB) and hepatosteatosis may lead to necroinflammation in liver. Therefore, the presence of hepatosteatosis might negatively affect the efficacy of antiviral therapy. We aimed to determine the effect of hepatosteatosis on virological response in patients with CHB receiving entecavir (ETV) and tenofovir (TDF) treatment.ArticleWOS:0005111735000098507786044310.5152/kd.2019.73